ABSTRACT
Background Organ availability limits kidney transplantation, the best treatment for end-stage kidney disease. Deceased donor acceptance criteria have been relaxed to include older donors with higher risk of inferior posttransplant outcomes. Donor age, although significantly correlates with transplant outcomes, lacks granularity in predicting graft dysfunction. Better characterization of the biological mechanisms associated with deceased donor organ damage and specifically predictive of transplant outcome in recipients is key to developing new assessment criteria for donor kidneys and developing function-preserving interventions.
Methods 185 deceased donor pretransplant biopsies with clinical and demographic donor and recipient metadata were obtained from the Quality in Organ Donation biobank (QUOD), selected on the basis of 12-month paired posttransplant function and deep proteomic profiles acquired by mass spectrometry. Using a 2/3rd:1/3rd training:test data split, sampling equally across posttransplant function, we applied machine learning feature selection followed by protein-wise relaxed LASSO regression modeling, assessing the performance of the final set of protein models on the test data. Western blotting validated protein changes, and the biological relevance of the final set of protein models was externally validated by contextualization against a published dataset of human healthy and disease kidney transcriptomes.
Results Our analysis revealed 144 proteins carrying outcome-predictive information, all of which showed donor-age modulated associations with posttransplant function, as opposed to age and protein/gene effects being independent terms. Observed associations with inflammatory, metabolic, protein processing and cell cycle pathways suggest biological targets for possible interventions pretransplant. Contextualization of our results against external spatial transcriptomic data suggest a sub-nephrotic spatial localization of the predictive signal.
Conclusions Integrating kidney proteome information with clinical metadata enhances the resolution of donor kidney quality stratification, and the highlighted biological mechanisms open new research directions in developing predictive models and novel interventions during donor management or preservation to improve kidney transplant outcome.
SIGNIFICANCE STATEMENT Currently, organ quality assessment pretransplant relies on key factors such as donor age or clinical information, these lack granularity in depicting graft susceptibility and capacity to function posttransplant. A high-resolution proteomic profiling of 185 pretransplant biopsies of kidneys with known posttransplant function and complete metadata was performed. Integration of donor kidney proteomes with 56 clinical metadata variables using regularized regression modelling resulted in enhancing the resolution of donor kidney quality stratification. Immunometabolic and catabolic processes contributed to donor kidney susceptibility and worse transplant outcomes in an age modulated pattern, validated by western blotting. Comparison of kidney proteomes with a recent transcriptomics dataset of healthy and diseased kidneys provide an additional special single cell resolution to the findings of this study.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by NHS Blood and Transplant WP15-07 awarded to MK & RJP. SF was supported by Kidney Research UK, grant reference KS_RP_002_20210111 awarded to MK. PDC was supported by a Chinese Academy of Medical Sciences 2018-I2M-2-002 awarded to BMK.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NHS Health Authority, National Research Ethics Service, gave ethical approval for IRAS project ID: 87824, Quality in Organ Donation (QUOD) (NW/18/0187), sponsored by University of Oxford
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Manuscript revised to include a revised analysis workflow reporting an expanded list of identified proteins and orthogonal contextualisation in a recently published independent dataset. Methods, results and discussion expanded to include additional analysis and findings. Figures and supplemental figures and tables revised.
Data Availability
The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE 67 partner repository with the dataset identifier PXD033428. All other data produced are contained in the manuscript or supplemental materials.
